Skip to content

Monitoring Cellular Immunity After Kidney and Liver Transplantation

Monitoring Cellular Immunity After Kidney and Liver Transplantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00683748
Enrollment
100
Registered
2008-05-23
Start date
2007-03-31
Completion date
2009-03-31
Last updated
2009-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Terminal Kidney Failure, Terminal Liver Failure

Keywords

Transplantation, Immunological monitoring, Immunological risk, T cell reactivity, Cellular immunity

Brief summary

After transplantation, if insufficient immunosuppression is achieved, rejection and graft loss follows. If to much immunosuppression is given, the patient suffers risk for infections and malignancies. Despite careful dosing and monitoring of drug levels, the biological effects of the immunosuppression given is difficult to predict and varies significantly. As a result, the degree of immunosuppression (or immunosuppressive status) remains unknown and clinical problems related to under- or over-immunosuppression are common. Thus, a method to determine the degree of immunosuppression would be of great and direct clinical importance and the results would be improved. T cells are the principal cells of the immunesystem causing rejection. Furthermore, all immunosuppressive regimes targets T cells. Thus, T cell reactivity could reflect the biological effects of the immunosuppression and the immunosuppressive status. In addition, T cells are of crucial importance in the immunedefence against viral diseases. Therefore, data on virus specific T cell reactivity could aid in diagnosis, monitoring and treatment of viral disease. The proposed study aim to develop a clinically useful method to monitor cellular immunity and the degree of immunosuppression after transplantation by determinations of the specific T cell reactivity to several clinically relevant viruses.

Interventions

None listed

Sponsors

Uppsala University Hospital
CollaboratorOTHER
Karolinska University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients undergoing kidney or liver transplantation at the Karolinska University Hospital

Exclusion criteria

* Abscence of informed consent

Design outcomes

Primary

MeasureTime frame
T cell reactivity to viral antigensPre-transplantation and 2 weeks, 1, 3, 6 and 12 months after transplantation

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026